We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
La Jolla Pharmaceutical Company | NASDAQ:LJPC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.23 | 6.54 | 6.25 | 0 | 01:00:00 |
|
|
|
|
|
|
|
|
|
|
|
|
California
|
|
33-0361285
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
|
Title of Securities
to be Registered
|
Amount
to be
Registered (1)
|
Proposed
Maximum
Offering Price
per Share (3)
|
Proposed
Maximum
Aggregate
Offering Price (3)
|
Amount of
Registration
Fee
|
Common Stock, $0.0001 par value per share (2)
|
3,500,000
|
$32.33
|
$113,155,000
|
$14,087.80
|
(1)
|
Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act") this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or similar transaction under the anti-dilution provisions of the standalone inducement awards or the registrant's 2013 Equity Incentive Plan, as amended (the "2013 Plan") or the forms of awards granted thereunder.
|
|
|
(2)
|
Represents shares of Common Stock reserved for issuance pursuant to the 2013 Plan.
|
|
|
(3)
|
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and (h) of the Securities Act, and based on the average of the per share high and low sale prices of the Registrant’s Common Stock, as quoted on The NASDAQ Capital Markets on October 26, 2017 which was $32.33.
|
|
|
|
•
|
The Company's Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on February 23, 2017, as amended on April 28, 2017 (the "Annual Report");
|
•
|
All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") since the end of the fiscal year covered by the Annual Report (other than the portions of these documents not deemed to be filed);
|
•
|
The description of the Company's Common Stock contained in Amendment No. 1 to that certain registration statement on Form 8-A (File No. 001-36282), filed with the Commission on October 17, 2014 pursuant to Section 12 of the Exchange Act, including any subsequent amendment or report filed for the purpose of updating that description; and
|
•
|
All documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules and regulations of the SEC shall not be deemed to be incorporated by reference herein into this Registration Statement.
|
|
|
|
|
Incorporated by Reference
|
|
|
||
Exhibit
No.
|
|
Exhibit
Description
|
|
Form
|
|
Date
Filed
|
|
Filed
Herewith
|
|
|
S-8
|
|
12/20/2013
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
8-K
|
|
1/15/2014
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
8-A/A
|
|
10/17/2014
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
8-A/A
|
|
10/17/2014
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
DEF 14A
|
|
7/31/2017
|
|
|
1.
|
Previously filed with the Company’s Form S-8 as Exhibit 4.1 as filed with the Commission on December 20, 2013 and incorporated by reference herein.
|
2.
|
Previously filed with the Company’s Current Report on Form 8-K as Exhibit
3.
1 as filed with the Commission on January 15, 2014 and incorporated by reference herein.
|
3.
|
Previously filed with the Company’s Form 8-A/A as Exhibit 3.3 as filed with the Commission on October 17, 2014 and incorporated by reference herein.
|
4.
|
Previously filed with the Company’s Form 8-A/A as Exhibit 3.4 as filed with the Commission on October 17, 2014 and incorporated by reference herein.
|
5.
|
Filed as Appendix A to the Company's Proxy Statement filed July 31, 2017 and incorporated herein by reference.
|
|
|
|
LA JOLLA PHARMACEUTICAL COMPANY
|
|
|
|
|
|
|
By:
|
/s/ George F. Tidmarsh, M.D., Ph.D.
|
|
|
Name:
|
George F. Tidmarsh, M.D., Ph.D.
|
|
|
Title:
|
President and Chief Executive Officer
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
/s/ George F. Tidmarsh, M.D., Ph.D.
|
|
Director, President, Chief Executive Officer and Secretary
(Principal Executive Officer)
|
|
October 27, 2017
|
|
George F. Tidmarsh, M.D., Ph.D.
|
|
|
|
||
|
|
|
|
|
|
/s/ Dennis M. Mulroy
|
|
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
|
October 27, 2017
|
|
Dennis M. Mulroy
|
|
|
|
||
|
|
|
|
|
|
/s/ Kevin C. Tang
|
|
Director, Chairman of the Board
|
|
October 27, 2017
|
|
Kevin C. Tang
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Laura L. Douglass
|
|
Director
|
|
October 27, 2017
|
|
Laura L. Douglass
|
|
|
|
||
|
|
|
|
|
|
/s/ Craig A. Johnson
|
|
Director
|
|
October 27, 2017
|
|
Craig A. Johnson
|
|
|
|
||
|
|
|
|
|
|
/s/ Robert H. Rosen
|
|
Director
|
|
October 27, 2017
|
|
Robert H. Rosen
|
|
|
|
|
|
|
|
Incorporated by Reference
|
|
|
||
Exhibit
No.
|
|
Exhibit
Description
|
|
Form
|
|
Date
Filed
|
|
Filed
Herewith
|
|
|
S-8
|
|
12/20/2013
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
8-K
|
|
1/15/2014
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
8-A/A
|
|
10/17/2014
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
8-A/A
|
|
10/17/2014
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
DEF 14A
|
|
7/31/2017
|
|
|
1.
|
Previously filed with the Company’s Form S-8 as Exhibit 4.1 as filed with the Commission on December 20, 2013 and incorporated by reference herein.
|
2.
|
Previously filed with the Company’s Current Report on Form 8-K as Exhibit 3.1 as filed with the Commission on January 15, 2014 and incorporated by reference herein.
|
3.
|
Previously filed with the Company’s Form 8-A/A as Exhibit 3.3 as filed with the Commission on October 17, 2014 and incorporated by reference herein.
|
4.
|
Previously filed with the Company’s Form 8-A/A as Exhibit 3.4 as filed with the Commission on October 17, 2014 and incorporated by reference herein.
|
5.
|
Filed as Appendix A to the Company's Proxy Statement filed July 31, 2017 and incorporated herein by reference.
|
1 Year La Jolla Pharmaceutical Chart |
1 Month La Jolla Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions